RA Capital Management, L.P., a director at Bambusa Therapeutics, Inc., buys $46.6M of stock
An open-market purchase between Oct 30 and Nov 2, reported to the SEC on Nov 3.
A Form 4 filed on Nov 3 shows RA Capital Management, L.P. (Director) buying 2,953,820 Bambusa Therapeutics, Inc. shares worth about $47 million between Oct 30 and Nov 2.
It is an open-market purchase (transaction code P) of common stock, the kind of trade insiders make with their own money. The trade was reported within two business days, as Section 16 requires.
Other Bambusa Therapeutics, Inc. insiders have also bought: Three insiders made open-market purchases within 14 days, a pattern known as a cluster buy.
Figures come from the Form 4 filed with the SEC; the table lists the open-market rows this article covers.
| Company | Bambusa Therapeutics, Inc. (BBTX) |
|---|---|
| Insider | RA Capital Management, L.P. |
| Role | Director |
| Transaction | Open-market purchase (code P) |
| Shares | 2,953,820 |
| Average price | $15.79 |
| Value | $46,639,958 |
| Trade dates | Oct 30 to Nov 2, 2026 |
| Filed with the SEC | Nov 3, 2026, 6:09 PM ET |
| Ownership | Indirect |
| Rule 10b5-1 plan | Not marked in the filing |
See more details on this insider purchase
See more large insider purchases · See the biggest insider trades of each day
Source: SEC Form 4. Information only, not investment advice. Not affiliated with or endorsed by the U.S. Securities and Exchange Commission.
